# US 2019/0241670 A1 · A monoclonal antibody and a method of use for the treatment of lupus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0241670 A1
- Document ID: US20190241670A1
- Status: Published application
- Kind: A1
- Application number: 16/343,127
- Filed: 2017-10-17
- Published: 2019-08-08
- Earliest claimed: 2016-10-21
- Assignees: Biocon Limited
- Applicants: Biocon Limited
- Inventors: Pradip NAIR; Ravindra Belavinakodige SADASHIVARAO; Ramakrishnan MELARKODE
- Web page: https://patentgrep.com/patent/US20190241670A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/39541: {against normal tissues, cells}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/18: against material from animals or humans
- A61K 2039/505: {comprising antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions and methods useful for the treatment of lupus using a humanized IgG1 anti-CD6 monoclonal antibody (T1h) that binds to the SRCR domain 1 (D1) of CD6 without blocking the interaction of CD6 with the CD6 ligand Activated Leukocyte Cell Adhesion Molecule (ALCAM).

## Claims

### Claim 1

A composition for treating lupus in a subject comprising an anti-CD6 monoclonal antibody (T1h) that binds to domain 1 (D1) of CD6 without interfering with ALCAM binding to CD6, wherein the anti-CD6 monoclonal antibody comprises amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, and wherein the anti-CD6 monoclonal antibody is in a therapeutically effective amount to reduce the symptoms of lupus in the subject.

### Claim 2 (depends on 1)

The composition of claim 1, wherein lupus comprises systemic lupus erythematosus, lupus nephritis, cutaneous lupus erythematosus, central nervous system (CNS) lupus, neonatal lupus erythematosus, childhood systemic lupus erythematosus, drug-induced lupus erythematosus or complement deficiency syndromes resulting in lupus manifestations.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the symptoms of lupus comprise cardiovascular manifestations, pulmonary manifestations, hepatic manifestations, haematologieal manifestations, gastrointestinal manifestations and/or musculoskeletal manifestations.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the anti-CD6 monoclonal antibody reduces or prevents the activation of T-cells, inhibits T-cell proliferation and/or reduces induction of complement-dependent cytotoxicity (CDC).

### Claim 5 (depends on 1)

The composition of claim 1, wherein the anti-CD6 monoclonal antibody is encoded by a nucleotide sequence comprising SEQ ID NO: 3 and SEQ ID NO: 4 or nucleotide sequences have at least 90% identity thereto and encodes for SEQ ID NO: 1 and SEQ ID NO: 2.

### Claim 6 (depends on 1)

The composition of claim 1, formulated for delivery by parenteral administration.

### Claim 7 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the anti-CD6 monoclonal antibody is combined with a chemotherapeutic agent, an immunosuppressive agent, an anti-malarial drug, a cytotoxic agent, an integrin antagonist, a cytokine antagonist, or a hormone.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the immunosuppressant is prednisone, methotrexate, azathioprine or cyclophosphamide.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the therapeutically effective amount is about 0.01 to about 100 mg/kg per subject body weight.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the anti-CD6 monoclonal antibody causes a reduction in pro inflammatory cytokines.

### Claim 12

A method for treating lupus in a subject comprising administering an anti-CD6 monoclonal antibody (T1h) that binds to domain 1 (D1) of CD6 without interfering with ALCAM binding to CD6, wherein the anti-CD6 monoclonal antibody comprises amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, and wherein the anti-CD6 monoclonal antibody is in a therapeutically effective amount to reduce the symptoms of lupus in the treated subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein lupus comprises systemic lupus erythematosus, lupus nephritis, cutaneous lupus erythematosus, central nervous system (CNS) lupus, neonatal lupus erythematosus, childhood systemic lupus erythematosus, drug-induced lupus erythematosus or complement deficiency syndromes resulting in lupus manifestations.

### Claim 14 (depends on 12)

The method of claim 12, wherein the symptoms of lupus comprise cardiovascular manifestations, pulmonary manifestations, hepatic manifestations, haematologieal manifestations, gastrointestinal manifestations and/or musculoskeletal manifestations.

### Claim 15 (depends on 12)

The method of claim 12, wherein the anti-CD6 monoclonal antibody reduces or prevents the activation of T-cells, inhibits T-cell proliferation and/or reduces induction of complement-dependent cytotoxicity (CDC).

### Claim 16 (depends on 12)

The method of claim 12, wherein the anti-CD6 monoclonal antibody is encoded by a nucleotide sequence comprising SEQ ID NO: 3 and SEQ ID NO: 4 or nucleotide sequences have at least 90% identity thereto and encodes for SEQ ID NO: 1 and SEQ ID NO: 2.

### Claim 17 (depends on 12)

The method of claim 12, wherein the anti-CD6 monoclonal antibody is administered by parenteral delivery.

### Claim 18 (depends on 12)

The method of claim 12, further comprising combining the anti-CD6 monoclonal antibody with a pharmaceutically acceptable carrier.

### Claim 19 (depends on 12)

The method of claim 12, wherein the anti-CD6 monoclonal antibody is combined with a chemotherapeutic agent, an immunosuppressive agent, an anti-malarial drug, a cytotoxic agent, an integrin antagonist, a cytokine antagonist or a hormone.

### Claim 20 (depends on 12)

The composition of claim 12, wherein the therapeutically effective amount is about 0.01 to about 100 mg/kg per subject body weight.

### Claim 21 (depends on 12)

The method of claim 12, wherein the anti-CD6 monoclonal antibody causes a reduction in pro inflammatory cytokines.

### Claim 22 (depends on 12)

The method of claim 12, wherein the subject does not have an autoimmune disease other than lupus.

### Claim 23

A method to reduce activation of T-cells in a subject patient with an elevated level of anti-nuclear antibodies (ANA) and/or anti-double-stranded DNA (dsDNA) antibodies, the method comprising administering to the subject a therapeutically effective amount of an anti-CD6 monoclonal antibody, wherein the anti-CD6 monoclonal antibody comprises amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2.

### Claim 24 (depends on 23)

The method of claim 23, wherein the therapeutically effective amount is about 0.01 to about 100 mg/kg per subject body weight.

### Claim 25

Use of an anti-CD6 monoclonal antibody in the manufacture of medicament useful for the treatment of lupus, wherein the wherein the anti-CD6 monoclonal antibody comprises amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2.
